10x Genomics First to Market With Product to Simultaneously Capture Epigenome and Transcriptome
September 15 2020 - 8:00AM
10x Genomics (Nasdaq: TXG) today announced it has begun shipping
its Chromium Single Cell Multiome ATAC + Gene Expression solution
to customers, marking the first commercial release of a product
capable of simultaneously profiling the epigenome and transcriptome
from the same single cell. This multi-omic approach provides
customers with the ability to link a cell’s epigenetic program to
its transcriptional output, enabling a better understanding of cell
functionality and bypassing the need to infer relationships through
computer simulations.
“This is one of our most ambitious undertakings at the company,”
said Ben Hindson, co-founder and Chief Scientific Officer of 10x
Genomics. “By introducing the first solution that captures ATAC and
gene expression simultaneously, researchers can gain even more
clarity by combining two already powerful methods to profile
biological systems at single cell resolution simultaneously for the
first time.”
The new solution builds on an array of new products launched by
the company this year for both its Chromium platform for single
cell analysis as well as its Visium platform for spatial
genomics. Early customers already working with Chromium
Single Cell Multiome ATAC + Gene Expression include Stanford
University School of Medicine, Icahn School of Medicine at Mt.
Sinai and Spain’s Centro Nacional de Análisis Genómico.
“My lab is interested in understanding why some immune cell
types fail to fight the cancer,” said Dr. Ansuman Satpathy,
Assistant Professor of Pathology, Stanford University School of
Medicine. “We plan to use 10x Genomics' new assay to understand the
epigenetic and transcriptional regulation of immune cell
dysfunction directly in patient samples, and to use this
information to precisely engineer more effective immunotherapies in
the future.”
“Until now, we have relied on computational prediction to match
a cell's epigenome to a single-cell gene expression profile,” said
Dr. Holger Heyn, leader of the single cell genomics team at Spain’s
Centro Nacional de Análisis Genómico that is working on delineating
the dynamics underlying B-cell differentiation and activation. “10x
Genomics new multiome assay will allow us to directly measure what
before could only be predicted, and offers a new gold standard that
will confirm how accurate these predictions had been.”
"With this new technology, we can better understand the
mechanisms affected by the non-coding risk genetic variation across
a wide range of neuropsychiatric diseases, including Alzheimer’s,
Parkinson’s, Schizophrenia, bipolar disorder and major depression,
along with different severity of neuropathology and clinical
symptomatology," added Dr. Panagiotis Roussos, Associate Professor
of Genetics and Genomics Sciences, Icahn School of Medicine at
Mount Sinai.
By using Chromium Single Cell Multiome ATAC + Gene Expression,
researchers can:
- Deepen their characterization of cell types and states with
linked transcriptional and epigenomic analyses
- Discover cells with similar transcriptional profiles but
functionally different chromatin landscapes
- Combine discovery of regulatory elements with gene expression
to explore gene regulatory interactions driving cell
differentiation, development, and disease
- Easily interpret epigenetic profiles with key expression
markers
- Maximize insights from precious samples with multiple readouts
from the same cell
Chromium Single Cell Multiome ATAC + Gene Expression is shipping
to customers. To learn more, visit
https://www.10xgenomics.com/products/single-cell-multiome-atac-plus-gene-expression.
About 10x Genomics10x Genomics is a life
science technology company building products to interrogate,
understand and master biology to advance human health. The
company’s integrated solutions include instruments, consumables and
software for analyzing biological systems at a resolution and scale
that matches the complexity of biology. 10x Genomics products have
been adopted by researchers around the world including 97 of the
top 100 global research institutions and 19 of the top 20 global
pharmaceutical companies, and have been cited in over 1,500
research papers on discoveries ranging from oncology to immunology
and neuroscience. The company’s patent portfolio comprises more
than 775 issued patents and patent applications.
Forward Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 as contained in
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements generally can be identified by the use
of forward-looking terminology such as “may,” “will,” “should,”
“expect,” “plan,” “anticipate,” “could,” “intend,” “target,”
“project” “contemplate,” “believe,” “estimate,” “predict,”
“potential” or “continue” or the negatives of these terms or
variations of them or similar terminology. These
forward-looking statements include statements regarding 10x
Genomics, Inc.’s partnership activities, which involve risks and
uncertainties that could cause 10x Genomics, Inc.’s actual results
to differ materially from the anticipated results and expectations
expressed in these forward-looking statements. These statements are
based on management’s current expectations, forecasts, beliefs,
assumptions and information currently available to management, and
actual outcomes and results could differ materially from these
statements due to a number of factors. These and additional risks
and uncertainties that could affect 10x Genomics, Inc.’s financial
and operating results and cause actual results to differ materially
from those indicated by the forward-looking statements made in this
press release include those discussed under the captions "Risk
Factors" and "Management's Discussion and Analysis of Financial
Condition and Results of Operations" and elsewhere in the documents
10x Genomics, Inc. files with the Securities and Exchange
Commission from time to time. The forward-looking statements in
this press release are based on information available to 10x
Genomics, Inc. as of the date hereof, and 10x Genomics, Inc.
disclaims any obligation to update any forward-looking statements
provided to reflect any change in its expectations or any change in
events, conditions, or circumstances on which any such statement is
based, except as required by law. These forward-looking statements
should not be relied upon as representing 10x Genomics, Inc.’s
views as of any date subsequent to the date of this press
release.
Disclosure Information10x Genomics uses filings
with the Securities and Exchange Commission, its website
(www.10xgenomics.com), press releases, public conference calls,
public webcasts and its social media accounts as means of
disclosing material non-public information and for complying with
its disclosure obligations under Regulation FD.
ContactsMedia:media@10xgenomics.comInvestors:investors@10xgenomics.com
10x Genomics (NASDAQ:TXG)
Historical Stock Chart
From Apr 2024 to May 2024
10x Genomics (NASDAQ:TXG)
Historical Stock Chart
From May 2023 to May 2024